Increased epidermal calmodulin (CaM) levels have been reported in psoriatic lesions. It has been suggested that CaM inhibition might be of relevance in the treatment of psoriasis vulgaris. Therefore we investigated the possible CaM inhibition by the antipsoriatic drug anthralin in vitro and in vivo. For in vitro studies, anthralin (0.44 mM) effects on the CaM-dependent Ca++-ATPase of CaM-depleted erythrocyte ghosts were assessed. At 100 μM Ca++ no enzyme inhibition was measured either in the presence or absence of CaM. At 2 μM Ca++ anthralin inhibited the CaM stimulation of membrane-bound ATPase for 50% in presence of CaM. For in vivo studies, skin biopsies were taken from anthralin-treated psoriatic lesions without scaling but still palpable infiltration during the first 3 weeks of therapy. Lesions with anthralin-induced irritation were excluded. The epidermal CaM level was determined by measuring the ability of soluble epidermal protein to activate the Ca++-ATPase in CaM-depleted erythrocyte ghosts. Epidermal CaM was 7.07 ± 4.57 (mean ± SD) μg CaM/mg soluble epidermal protein. This is a 6-fold increase compared to normal human epidermis and a 3-fold increase compared to nontreated lesional psoriatic epidermis (p < 0.01 and 0.02, respectively). The results argue against CaM inhibition of psoriatic epidermal keratinocytes as the primary event in the antipsoriatic action of anthralin.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.